Skip to main content
Contact Us
Subscribe
E-Edition
63°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bluebird Bio
(NQ:
BLUE
)
0.9125
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bluebird Bio
< Previous
1
2
3
4
5
6
7
Next >
Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc. (NASDAQ: BLUE)
March 26, 2024
NEW YORK, NY - (NewMediaWire) - March 26, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click...
Via
NewMediaWire
Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc. (NASDAQ: BLUE)
March 26, 2024
NEW YORK, NY - (NewMediaWire) - March 26, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click...
Via
TheNewswire.com
bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
March 26, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
March 25, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
March 18, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
March 11, 2024
From
bluebird bio, Inc.
Via
Business Wire
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
March 06, 2024
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place
Via
MarketBeat
MarketBeat Week in Review – 2/26 - 3/1
March 02, 2024
As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
bluebird bio Stock Signals Potential to be a Multi-bagger
February 29, 2024
Driving a bargain of a short squeeze play, Bluebird Bio stock could soon announce what every investor is hoping to hear, here's what management could do
Via
MarketBeat
Topics
Economy
Exposures
Economy
bluebird bio: How to play LEAPS options for growth and income
February 27, 2024
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT
Via
MarketBeat
Exposures
Product Safety
bluebird bio stock is ripe for a 400% institutional short squeeze
February 27, 2024
Bluebird Bio stock could be on the verge of a 400% pop on earnings, management has set the writing on the wall for institutional buying to trickle in
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Is CRISPR Therapeutics the NVIDIA of gene editing?
February 26, 2024
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Gene therapy: Why does it cost millions for a single treatment?
February 15, 2024
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.
Via
MarketBeat
Exposures
Product Safety
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Exposures
Product Safety
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook
January 08, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
December 19, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
December 18, 2023
From
bluebird bio, Inc.
Via
Business Wire
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
December 10, 2023
From
bluebird bio, Inc.
Via
Business Wire
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
December 09, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
December 08, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
December 08, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
November 07, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
November 02, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
October 30, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Host Third Quarter 2023 Financial Results Conference Call
October 24, 2023
From
bluebird bio, Inc.
Via
Business Wire
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
bluebird bio Announces September Investor Events
September 05, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease
August 16, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
August 08, 2023
From
bluebird bio, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.